<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.119568</article-id><article-id pub-id-type="publisher-id">ACM-44988</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210900000_83358376.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  胺碘酮联合美托洛尔治疗心肌梗死合并快速心律失常患者疗效的META分析
  META-Analysis of Efficacy of the Amiodarone Combined with Metoprolol in Patients with Myocardial Infarction Complicated with Tachyarrhythmia
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>毕</surname><given-names>小雯</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>赵</surname><given-names>娜</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>燕</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>云法</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>郑</surname><given-names>雨</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>韩</surname><given-names>迪</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>青岛大学附属医院全科医学科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><aff id="aff2"><addr-line>青岛大学，山东 青岛</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>09</month><year>2021</year></pub-date><volume>11</volume><issue>09</issue><fpage>3876</fpage><lpage>3883</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：探讨胺碘酮联合美托洛尔对心肌梗死合并心律失常患者的效果。方法：检索EMbase、PubMed、知网、万方、Web of Science、维普、全球学术快报等数据库中从2015年始至2021年发表的文章，包括中文和英文。结果：最终纳入12篇文献RCTs进行META分析。与单用胺碘酮组比较，胺碘酮联合美托洛尔治疗MI合并快速心律失常可以增加MI患者转复快速心律失常的有效率(RR = 1.20，95%CI = 1.14~1.27，P = 0.00)；以及改善心功能LVESD (WMD = −7.59，95%CI = −8.55~−6.63，P = 0.00)；CO (WMD = 1.17，95%CI = 1.08~1.25，P = 0.00)而对LVEF (WMD = 9.60，95%CI = 7.93~11.27，P = 0.00)；LVEDD (WMD = −11.39，95%CI = −12.85~−9.92，P = 0.00)影响不大。结论：胺碘酮联合美托洛尔治疗MI合并快速心律失常患者可改善患者心功能，疗效显著，有助于患者的预后。
   Objective: To investigate the effect of amiodarone combined with metoprolol on patients with myocardial infarction complicated with arrhythmia. Methods: Literature published since 2015, including Chinese and English, were searched in EMbase PubMed, ZhiWang, Wanfang, Web of Science, VIP, Global Academic Express and other databases. Results: 12 literatures of RCTs were finally included for META analysis. Compared with the amiodarone alone group, amiodarone combined with metoprolol in the treatment of MI combined with tachyarrhythmia can increase the effective rate of MI patients to convert to tachyarrhythmia (RR = 1.20, 95%CI = 1.14~1.27, P = 0.00); and to improve cardiac function of LVESD (WMD = −7.59, 95%CI = −8.55~−6.63, P = 0.00); CO (WMD = 1.17, 95%CI = 1.08~1.25, P = 0.00), but has little effect on LVEF (WMD = 9.60, 95%CI = 7.93~11.27, P = 0.00); LVEDD (WMD = −11.39, 95%CI = −12.85~−9.92, P = 0.00). Conclusion: Amiodarone combined with metoprolol can improve the cardiac function of patients with MI complicated with tachyarrhythmia.
 
</p></abstract><kwd-group><kwd>胺碘酮，美托洛尔，心肌梗死，快速性心律失常，META分析, Amiodarone</kwd><kwd> Metoprolol</kwd><kwd> Myocardial Infarction</kwd><kwd> Tachyarrhythmia</kwd><kwd> META-Analysis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨胺碘酮联合美托洛尔对心肌梗死合并心律失常患者的效果。方法：检索EMbase、PubMed、知网、万方、Web of Science、维普、全球学术快报等数据库中从2015年始至2021年发表的文章，包括中文和英文。结果：最终纳入12篇文献RCTs进行META分析。与单用胺碘酮组比较，胺碘酮联合美托洛尔治疗MI合并快速心律失常可以增加MI患者转复快速心律失常的有效率(RR = 1.20，95%CI = 1.14~1.27，P = 0.00)；以及改善心功能LVESD (WMD = −7.59，95%CI = −8.55~−6.63，P = 0.00)；CO (WMD = 1.17，95%CI = 1.08~1.25，P = 0.00)而对LVEF (WMD = 9.60，95%CI = 7.93~11.27，P = 0.00)；LVEDD (WMD = −11.39，95%CI = −12.85~−9.92，P = 0.00)影响不大。结论：胺碘酮联合美托洛尔治疗MI合并快速心律失常患者可改善患者心功能，疗效显著，有助于患者的预后。</p></sec><sec id="s2"><title>关键词</title><p>胺碘酮，美托洛尔，心肌梗死，快速性心律失常，META分析</p></sec><sec id="s3"><title>META-Analysis of Efficacy of the Amiodarone Combined with Metoprolol in Patients with Myocardial Infarction Complicated with Tachyarrhythmia<sup> </sup></title><p>Xiaowen Bi<sup>1</sup>, Na Zhao<sup>1</sup>, Yan Wang<sup>2</sup>, Yunfa Li<sup>2</sup>, Yu Zheng<sup>2</sup>, Di Han<sup>2*</sup></p><p><sup>1</sup>Qingdao University, Qingdao Shandong</p><p><sup>2</sup>Department of General Medicine, Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/5-1572528x5_hanspub.png?20210906092352307" /></p><p>Received: Aug. 1<sup>st</sup>, 2021; accepted: Aug. 22<sup>nd</sup>, 2021; published: Sep. 3<sup>rd</sup>, 2021</p><p><img src="//html.hanspub.org/file/5-1572528x6_hanspub.png?20210906092352307" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To investigate the effect of amiodarone combined with metoprolol on patients with myocardial infarction complicated with arrhythmia. Methods: Literature published since 2015, including Chinese and English, were searched in EMbase PubMed, ZhiWang, Wanfang, Web of Science, VIP, Global Academic Express and other databases. Results: 12 literatures of RCTs were finally included for META analysis. Compared with the amiodarone alone group, amiodarone combined with metoprolol in the treatment of MI combined with tachyarrhythmia can increase the effective rate of MI patients to convert to tachyarrhythmia (RR = 1.20, 95%CI = 1.14~1.27, P = 0.00); and to improve cardiac function of LVESD (WMD = −7.59, 95%CI = −8.55~−6.63, P = 0.00); CO (WMD = 1.17, 95%CI = 1.08~1.25, P = 0.00), but has little effect on LVEF (WMD = 9.60, 95%CI = 7.93~11.27, P = 0.00); LVEDD (WMD = −11.39, 95%CI = −12.85~−9.92, P = 0.00). Conclusion: Amiodarone combined with metoprolol can improve the cardiac function of patients with MI complicated with tachyarrhythmia.</p><p>Keywords:Amiodarone, Metoprolol, Myocardial Infarction, Tachyarrhythmia, META-Analysis</p><disp-formula id="hanspub.44988-formula32"><graphic xlink:href="//html.hanspub.org/file/5-1572528x7_hanspub.png?20210906092352307"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/5-1572528x8_hanspub.png?20210906092352307" /> <img src="//html.hanspub.org/file/5-1572528x9_hanspub.png?20210906092352307" /></p></sec><sec id="s5"><title>1. 引言</title><p>心肌梗死是冠状动脉血供急剧减少或中断，使相应的心肌严重而持久地急性缺血所致 [<xref ref-type="bibr" rid="hanspub.44988-ref1">1</xref>]，从而导致左室舒张末期压增加，舒张和收缩末期容量增加，射血分数下降，心搏量和心排出量下降 [<xref ref-type="bibr" rid="hanspub.44988-ref2">2</xref>]。若在此基础上合并心律失常，时间过长且未进行有效治疗，心功能会严重受损并容易形成栓子，在脱落后进入循环系统进而堵塞血管形成血栓。胺碘酮与美托洛尔是目前治疗心律失常患者最为常见的两种抗心律失常药物。但单独用药的临床疗效欠佳，无法在短时间内快速有效地帮助患者稳定心室率，有研究建议两种药物联合应用，以提高临床治疗有效率与安全性 [<xref ref-type="bibr" rid="hanspub.44988-ref3">3</xref>]。该META分析目的是评估联合用药与单用胺碘酮相比，哪种治疗方式更有利于患者的症状改善及预后疗效。</p></sec><sec id="s6"><title>2. 纳入及排除标准</title><sec id="s6_1"><title>2.1. 纳入标准</title><p>1) 研究对象为心肌梗死合并快速心律失常患者；2) 干预措施为胺碘酮联合美托洛尔；3) 对照措施为单用胺碘酮；4) 观察结局：胺碘酮联合美托洛尔治疗心肌梗死合并快速心律失常疗效有效数。(有效数 = 显效数 + 有效数)。心功能：LVEF、LVEDD、LVESD、CO；5) 设计类型为随机对照试验。</p></sec><sec id="s6_2"><title>2.2. 排除标准</title><p>1) 与本次研究不相符合的文献；2) 文献分组没有分为胺碘酮联合美托洛尔组和胺碘酮组；3) 没有相应的预后效果指标及观察指标；4) 排除非随机对照试验的文献；5) 文献数据出现争议或者纰漏。</p></sec></sec><sec id="s7"><title>3. 文献检索</title><p>本次研究2位系统评价员对数据库进行检索，检索2015年1月至2021年4月的相关文献，检索的数据库有Embase、PubMed、知网、万方、Web of Science、维普、全球学术快报等数据库。中文检索词汇：胺碘酮、美托洛尔、心肌梗死合并心律失常、随机对照试验、META分析；英文检索词汇：“Miodarona”、“Toprol”、“Myocardial Infarctions”、“Arrhythmia”、“RCT”、“META-analysis”。</p></sec><sec id="s8"><title>4. 数据提取和质量评价</title><p>由2位系统评价员进行数据提取，信息包括作者、发表时间、期刊名称、研究类型、美托洛尔类型、联合组总有效数(总有效数 = 显效数 + 有效数)、联合组总例数(总例数 = 总有效数 + 无效数)等。质量评价由2位研究人员使用STATA16.0软件上的Cochrane风险偏倚评估工具对文献进行评价。</p></sec><sec id="s9"><title>5. 统计学方法与处理</title><p>使用 STATA16.0软件对数据进行处理，对计数资料选用包括RR、95%CI、I2和P值，对计量资料选用加权均数差(WMD)和95% (CI)用作功效分析统计数据。使用Cochrane系统评价的标准：I<sup>2</sup> ≤ 50%时提示存在较少异质性，使用固定效应模型；I<sup>2</sup> &gt; 50%，提示存在较大异质性，使用随机效应模型。</p><sec id="s9_1"><title>5.1. 文献检索结果</title><p>本次研究中共有448篇文献被检索纳入，其他方法未发现相关文献。流程图见图1，最终纳入12篇文献 [<xref ref-type="bibr" rid="hanspub.44988-ref4">4</xref>] - [<xref ref-type="bibr" rid="hanspub.44988-ref15">15</xref>]。数据提取最终总例数1063例，其中联合组总例数532例，胺碘酮组总例数531例。文献筛选流程(见图1)。</p><p>图1. 文献筛选流程图</p></sec><sec id="s9_2"><title>5.2. 数据提取</title><p>纳入的8篇文献关于风险偏倚评估工具的条目提及较少，如盲法的选择、随访及退出等都未进行说明，随机的方法仅有7篇文献进行了说明，5篇文献提及随机。可以认为本次研究的纳入的12篇文献质量介于低风险和高风险之间，质量尚可。具体文献质量的风险偏倚评估。具体拟纳入文献见表格(见表1)。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Basic characteristics and quality evaluation of the included studie</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >纳入文献</th><th align="center" valign="middle" >样本量</th><th align="center" valign="middle" >干预措施 观察组/实验组</th><th align="center" valign="middle" >随访时间</th><th align="center" valign="middle" >结局指标</th><th align="center" valign="middle" >盲法</th><th align="center" valign="middle" >分配隐藏</th><th align="center" valign="middle" >随机分配方法</th></tr></thead><tr><td align="center" valign="middle" >江玲2017</td><td align="center" valign="middle" >43/43</td><td align="center" valign="middle" >胺碘酮/美托洛尔 + 胺碘酮</td><td align="center" valign="middle" >3周</td><td align="center" valign="middle" >1234</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >随机平分法</td></tr><tr><td align="center" valign="middle" >刘西方2017</td><td align="center" valign="middle" >36/35</td><td align="center" valign="middle" >胺碘酮/美托洛尔 + 胺碘酮</td><td align="center" valign="middle" >2月</td><td align="center" valign="middle" >1245</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >随机数字表法</td></tr><tr><td align="center" valign="middle" >李西红2019</td><td align="center" valign="middle" >46/46</td><td align="center" valign="middle" >胺碘酮/美托洛尔 + 胺碘酮</td><td align="center" valign="middle" >3周</td><td align="center" valign="middle" >245</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >随机数字法</td></tr><tr><td align="center" valign="middle" >连会军2019</td><td align="center" valign="middle" >80/80</td><td align="center" valign="middle" >胺碘酮/美托洛尔 + 胺碘酮</td><td align="center" valign="middle" >3周</td><td align="center" valign="middle" >1245</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >电脑随机</td></tr><tr><td align="center" valign="middle" >吴艳丽2019</td><td align="center" valign="middle" >47/47</td><td align="center" valign="middle" >胺碘酮/美托洛尔 + 胺碘酮</td><td align="center" valign="middle" >2个月</td><td align="center" valign="middle" >1234</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >随机数字表法</td></tr><tr><td align="center" valign="middle" >池东阳2019</td><td align="center" valign="middle" >65/65</td><td align="center" valign="middle" >胺碘酮/美托洛尔 + 胺碘酮</td><td align="center" valign="middle" >60天</td><td align="center" valign="middle" >1245</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >提及随机</td></tr><tr><td align="center" valign="middle" >王莉君2019</td><td align="center" valign="middle" >20/20</td><td align="center" valign="middle" >胺碘酮/美托洛尔 + 胺碘酮</td><td align="center" valign="middle" >3个月</td><td align="center" valign="middle" >1234</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >提及随机</td></tr><tr><td align="center" valign="middle" >孙丽芳2019</td><td align="center" valign="middle" >23/23</td><td align="center" valign="middle" >胺碘酮/美托洛尔 + 胺碘酮</td><td align="center" valign="middle" >1个月</td><td align="center" valign="middle" >1234</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >提及随机</td></tr><tr><td align="center" valign="middle" >王明君2020</td><td align="center" valign="middle" >46/46</td><td align="center" valign="middle" >胺碘酮/美托洛尔 + 胺碘酮</td><td align="center" valign="middle" >3周</td><td align="center" valign="middle" >1245</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >提及随机</td></tr><tr><td align="center" valign="middle" >王伟2021</td><td align="center" valign="middle" >37/37</td><td align="center" valign="middle" >胺碘酮/美托洛尔 + 胺碘酮</td><td align="center" valign="middle" >3周</td><td align="center" valign="middle" >1245</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >提及随机</td></tr><tr><td align="center" valign="middle" >张学平2021</td><td align="center" valign="middle" >39/39</td><td align="center" valign="middle" >胺碘酮/美托洛尔 + 胺碘酮</td><td align="center" valign="middle" >2月</td><td align="center" valign="middle" >1245</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >提及随机</td></tr><tr><td align="center" valign="middle" >黎燕锋2020</td><td align="center" valign="middle" >50/50</td><td align="center" valign="middle" >胺碘酮/美托洛尔 + 胺碘酮</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1245</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >不清楚</td><td align="center" valign="middle" >提及随机</td></tr></tbody></table></table-wrap><p>表1. 纳入研究的基本特征及质量评价</p><p>注：结局指标：1) 有效率 = (显效数 + 有效数) &#215; 100%；2) 治疗后LVEF水平；3) 治疗后LVESD水平；4) 治疗后LVEDD水平；5) 治疗后CO水平。</p></sec></sec><sec id="s10"><title>6. META结果</title><sec id="s10_1"><title>6.1. 有效率</title><p>有11个研究报道了胺碘酮联合美托洛尔治疗心肌梗死合并心律失常患者的疗效的结果。各个研究结果间无统计学异质性I<sup>2</sup> = 0.00% &lt; 50%，选择固定效应模型。试验组与对照组比较，Z = 6.75 (P = 0.00 &lt; 0.05)，RR = 1.21，95%CI = (1.14, 1.28)，P = 0.00差异有统计学意义(见图2)。</p><p>图2. 两组患者治疗后有效率的META分析森林图</p></sec><sec id="s10_2"><title>6.2. 治疗后LVEF水平</title><p>有12个研究报道了治疗后患者的LVEF水平，I<sup>2</sup> = 81.36% &gt; 50%，采用随机模型后，Z = −11.27 (P = 0.00 &lt; 0.10)，WMD = 9.60，95%CI = (7.93, 11.27)结果提示两组间无统计学意义(见图3)。</p><p>图3. 两组患者治疗后LVEF水平的META分析森林图</p></sec><sec id="s10_3"><title>6.3. 治疗后LVESD水平</title><p>有4个研究报道了治疗后LVESD水平，I<sup>2</sup> &lt; 50%，选择固定效应模型，试验组与对照组比较，Z = −15.48 (P = 0.00 &lt; 0.05)，WMD = −7.59，95%CI = (−8.55, −6.63)，差异有统计学意义(见图4)。</p><p>图4. 两组患者治疗后LVESD水平的META分析森林图</p></sec><sec id="s10_4"><title>6.4. 治疗后LVEDD水平</title><p>有12个研究报道了治疗后LVEDD水平，结果显示：I<sup>2</sup> = 86.10% &gt; 50%，选择随机效应模型，试验组与对照组比较，Z = −15.21 (P = 0.00 &lt; 0.05)，WMD = −11.39，95%CI = (−12.85, −9.92)，采用随机模型后结果提示两组间无统计学意义，采用固定模型进行敏感性分析后仍提示无统计学意义(见图5)。</p><p>图5. 两组患者治疗后LVEDD水平的META分析森林图</p><p>图6. 两组患者治疗后CO水平的META分析森林图</p></sec><sec id="s10_5"><title>6.5. 治疗后CO水平</title><p>有8个研究报道了胺碘酮联合美托洛尔治疗心肌梗死合并心律失常患者的疗效的结果。I<sup>2</sup> &lt; 50%，选择固定效应模型，试验组与对照组比较，Z = 26.93 (P = 0.00 &lt; 0.05)，WMD = 1.17，95%CI = (1.08, 1.25)，差异有统计学意义(见图6)。</p></sec></sec><sec id="s11"><title>7. 讨论</title><p>心肌梗死是临床上心血管系统中一种急危重疾病，心肌梗死后出现心律失常是发生心室颤动的危险信号。然而，心肌梗死患者恢复期发生快速心律失常甚至心脏猝死，与心肌梗死后交感神经重构密切相关，其主要表现为去神经支配、交感神经芽及交感神经分布密度增高 [<xref ref-type="bibr" rid="hanspub.44988-ref16">16</xref>]。对于心肌梗死患者来说，控制心室率对患者心肌梗死预后，以及对患者心梗并发症的预防来说是重要的治疗手段。美托洛尔作为β肾上腺素受体阻断剂的一种，可通过选择性抑制心脏β1受体达到控制患者症状的目的。其能抑制过度激活的交感神经系统，对心脏产生抑制作用，从而控制心率，减弱心肌收缩力，减少心排出量 [<xref ref-type="bibr" rid="hanspub.44988-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.44988-ref18">18</xref>]。同时，美托洛尔还有降糖作用 [<xref ref-type="bibr" rid="hanspub.44988-ref19">19</xref>]，胺碘酮，作为III类抗心律失常药物，可以阻断K<sup>+</sup>通道 [<xref ref-type="bibr" rid="hanspub.44988-ref20">20</xref>]，可通过延长心肌细胞动作电位时程和有效不应期，延长Q-T间期和QRS波，从而控制心率，也可以抑制肾上腺受体，扩张冠脉及四周动脉，提高心脏射血功能。小剂量使用胺碘酮联合美托洛尔治疗 [<xref ref-type="bibr" rid="hanspub.44988-ref21">21</xref>] 与单用胺碘酮治疗相比，小剂量胺碘酮联合美托洛尔治疗心肌梗死合并快速心律失常患者至少治疗3周时间后可改善LVEF、LVESD、CO，即改善心功能。而对于LVEF、LVEDD的影响两者并无统计学意义。</p><p>本次研究的局限性：1) 纳入的研究个体数量有限，并且部分研究病例数较少，对于MI合并心律失常患者的疾病严重程度、患病时间、是否合并其他疾病有差异，其次对胺碘酮使用的方法存在差异，可能导致结果存在一定的异质性。2) 本系统评价仅纳入中文文献，可能会存在一定的系统误差。本研究所得结论仍需要更多大样本、高质量的RCTs进一步证实。3) 各个研究的关于纳入心律失常的类型并不完全一致以及胺碘酮与美托洛尔的应用剂量并不完全一致，可能会存在一定的误差。4) 各个研究中有效、显效的指标不一致，会造成一定的误差。</p><p>综上所述，对于MI后心律失常患者来说，应用美托洛尔联合胺碘酮治疗对患者的疗效及心功能的转归大有裨益。本研究是对心肌梗死后心律失常患者预后的研究，干预与对照措施均选用胺碘酮的口服制剂，但在心肌梗死急性发作期，若是合并心律失常，静脉胺碘酮用药对患者预后，即心功能的改善是否具有统计学意义还待进一步研究。另外，胺碘酮与美托洛尔之间是否存在某种药物作用 [<xref ref-type="bibr" rid="hanspub.44988-ref22">22</xref>] 以及哪种比例的最佳的药物配比更加适合于心肌梗死后心率失常患者还有待进一步研究。目前也有相关新的分子疗法对心肌梗死相关心律失常患者的治疗方案可供选择 [<xref ref-type="bibr" rid="hanspub.44988-ref23">23</xref>]，但其相对于药物、射频等治疗方法是否有更好的疗效还待进一步研究。</p></sec><sec id="s12"><title>文章引用</title><p>毕小雯,赵 娜,王 燕,李云法,郑 雨,韩 迪. 胺碘酮联合美托洛尔治疗心肌梗死合并快速心律失常患者疗效的META分析META-Analysis of Efficacy of the Amiodarone Combined with Metoprolol in Patients with Myocardial Infarction Complicated with Tachyarrhythmia[J]. 临床医学进展, 2021, 11(09): 3876-3883. https://doi.org/10.12677/ACM.2021.119568</p></sec><sec id="s13"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.44988-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Alpert, J.S., et al. (2000) Myocardial Infarction Redefined—A Consensus Document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. Journal of the American College of Cardiology, 36, 959-969. &lt;br&gt;https://doi.org/10.1016/S0735-1097(00)00804-4</mixed-citation></ref><ref id="hanspub.44988-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Smit, M., Coetzee, A.R. and Lochner, A. (2020) The Pathophysiology of Myocardial Ischemia and Perioperative Myocardial Infarction. Journal of Cardiothoracic and Vascular Anesthesia, 34, 2501-2512.  
&lt;br&gt;https://doi.org/10.1053/j.jvca.2019.10.005</mixed-citation></ref><ref id="hanspub.44988-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">刘华伟. 胺碘酮联合美托洛尔治疗心律失常患者的临床研究进展[J]. 医疗装备, 2021, 34(6): 193-195.</mixed-citation></ref><ref id="hanspub.44988-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">江玲, 等. 美托洛尔联合胺碘酮治疗AMI并发快速心律失常的可行性及安全性[J]. 现代诊断与治疗, 2017, 28(21): 3986-3988.</mixed-citation></ref><ref id="hanspub.44988-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">李西红, 孙黎博. 胺碘酮联合美托洛尔治疗急性心肌梗死合并心律失常患者的效果及对患者心脏功能的影响分析[J]. 山西医药杂志, 2019, 48(22): 2734-2737.</mixed-citation></ref><ref id="hanspub.44988-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">连会军. 胺碘酮联合美托洛尔治疗急性心肌梗死合并心律失常患者的效果及对患者心脏功能的影响[J]. 中国民间疗法, 2019, 27(12): 75-77.</mixed-citation></ref><ref id="hanspub.44988-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">刘佳佳, 曹宇, 盛喆. 冠状动脉钙化的病理生理机制及钙化评估进展[J]. 临床心血管病杂志, 2020, 36(8): 768-772.</mixed-citation></ref><ref id="hanspub.44988-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">王明君, 崔众芹. 胺碘酮联合美托洛尔对急性心肌梗死合并心律失常患者心脏功能的影响[J]. 中国社区医师, 2020, 36(9): 42-43.</mixed-citation></ref><ref id="hanspub.44988-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">王伟. 美托洛尔联合胺碘酮治疗急性心肌梗死合并心律失常患者的效果[J]. 中国民康医学, 2021, 33(2): 26-28.</mixed-citation></ref><ref id="hanspub.44988-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">吴艳丽, 路素品. 美托洛尔联合胺碘酮治疗急性心肌梗死并发快速性心律失常[J]. 实用中西医结合临床, 2019, 19(8): 67-68.</mixed-citation></ref><ref id="hanspub.44988-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">张学平, 等. 胺碘酮联合美托洛尔治疗急性心肌梗死合并心律失常的效果观察[J]. 中国实用医刊, 2021, 48(3): 100-102.</mixed-citation></ref><ref id="hanspub.44988-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">池东阳, 丁福祥. 胺碘酮联合琥珀酸美托洛尔对急性心肌梗死并室性心律失常患者心功能的影响[J]. 医学食疗与健康, 2019(15): 91, 93.</mixed-citation></ref><ref id="hanspub.44988-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">孙丽芳. 胺碘酮联合β受体阻滞剂治疗急性心肌梗死并发快速心律失常的效果观察[J]. 中国民康医学, 2019, 31(23): 15-17.</mixed-citation></ref><ref id="hanspub.44988-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">王莉君, 刘晓梅. 胺碘酮联合β受体阻滞剂治疗急性心肌梗死并发快速心律失常的疗效及安全性[J]. 现代医药卫生, 2019, 35(8): 1223-1225.</mixed-citation></ref><ref id="hanspub.44988-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">黎燕锋. 胺碘酮联合美托洛尔对急性心肌梗死合并心律失常患者心脏功能的影响研究[J]. 吉林医学, 2021, 42(5): 1124-1125.</mixed-citation></ref><ref id="hanspub.44988-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Yu, T.S., Ge, L.Z. and Cao, J.M. (2019) Research Advances in Sympathetic Remodeling after Myocardial Infarction and Its Significance in Forensic Science. Scimago Journal &amp; Country Rank, 35, 68-73.</mixed-citation></ref><ref id="hanspub.44988-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Liqun, Z., et al. (2021) Metoprolol Attenuates Intracerebral Hemorrhage-Induced Cardiac Damage by Suppression of Sympathetic Overactivity in Mice. Autonomic Neuroscience, 234, Article ID: 102832.  
&lt;br&gt;https://doi.org/10.1016/j.autneu.2021.102832</mixed-citation></ref><ref id="hanspub.44988-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Pakkir, M.N.M., et al. (2021) A Review on Pharmacokinetic and Pharmacodynamic Drug Interactions of Adrenergic β-Blockers with Clinically Relevant Drugs—An Overview. Current Drug Metabolism.</mixed-citation></ref><ref id="hanspub.44988-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Eylem, C., et al. (2021) The Prophylactic Effects of Metoprolol, Diltiazem, and Pilocarpine on Hypoglycemia-Induced Prolongation of QT Interval. Cureus, 13, e14058.</mixed-citation></ref><ref id="hanspub.44988-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Staudacher, I., et al. (2018) Cardiovascular Pharmacology of K(2P)17.1 (TASK-4, TALK-2) Two-Pore-Domain K(+) channels. Naunyn-Schmiedeberg’s Archives of Pharmacology, 391, 1119-1131.  
&lt;br&gt;https://doi.org/10.1007/s00210-018-1535-z</mixed-citation></ref><ref id="hanspub.44988-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Damien, B., et al. (2021) Beyond-Use Dates Assignment for Pharmaceutical Preparations: Example of Low-Dose Amiodarone Capsules. Journal of Pharmacy Technology, 37, 178-185. &lt;br&gt;https://doi.org/10.1177/87551225211015566</mixed-citation></ref><ref id="hanspub.44988-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">McDonald, M.G., Au, N.T. and Rettie, A.E. (2015) P450-Based Drug-Drug Interactions of Amiodarone and Its Metabolites: Diversity of Inhibitory Mechanisms. Drug Metabolism and Disposition, 43, 1661-1669.  
&lt;br&gt;https://doi.org/10.1124/dmd.115.065623</mixed-citation></ref><ref id="hanspub.44988-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Driessen, H.E., van Veen, T.A.B. and Boink, G.J.J. (2017) Emerging Molecular Therapies Targeting Myocardial Infarction-Related Arrhythmias. Europace, 19, 518-528. &lt;br&gt;https://doi.org/10.1093/europace/euw198</mixed-citation></ref></ref-list></back></article>